• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Zymeworks Inc. - Common Stock (NQ:ZYME)

    29.26 -1.68 (-5.43%)
    Delayed Quote Updated: 2:04 PM EST, Nov 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 718,051
    Open 30.85
    Bid (Size) 29.18 (800)
    Ask (Size) 29.30 (100)
    Prev. Close 30.94
    Today's Range 29.14 - 30.91
    52wk Range 16.00 - 31.49
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside ↗
    Zymeworks (NASDAQ:ZYME) outlined a partnering-focused research strategy, presented updated clinical data for its ZW191 antibody-drug conjugate in platinum-resistant ovarian cancer, and discussed its... 
    Via MarketBeat
    News headline image
    Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
    From Zymeworks Inc.
    Via GlobeNewswire

    Performance

    52-Week Range 7.1% below 52-week high
    29.26
    16.0052W Low 31.4952W High
    1 Week 7.1% below 1-week high
    28.261W Low 31.491W High

    Zymeworks Inc. - Common Stock (ZYME) traded between $16.00 and $31.49 over the past 52 weeks and last traded at $29.26, 7.1% below its 52-week high. Over the past week it ranged between $28.26 and $31.49.

    Past 12 Months
    +1.9%
    +11.6%
    +24.5%
    +6.0%
    +9.9%
    +61.1%
    1W +$0.55
    1M +$3.05
    3M +$5.76
    6M +$1.65
    YTD +$2.64
    1Y +$11.10

    ZYME was +61.1% over the past year, +6.0% over six months, +9.9% year to date, +1.9% in the last week.

    12 Months vs Market
    ZYME
    +61.1%
    DIA
    +9.4%
    SPY
    +8.8%
    QQQ
    +5.7%
    IWM
    +12.3%

    Over the past 12 months ZYME returned +61.1% versus DIA (Dow) +9.4%, SPY (S&P 500) +8.8%, QQQ (Nasdaq 100) +5.7% and IWM (Russell 2000) +12.3%.

    Volume & Liquidity 0.71× 3-mo avg
    Today 718,051 3-mo avg 1.0M
    1W
    1.7M
    1M
    1.4M
    3M
    1.0M
    6M
    821.4K
    YTD
    777.1K
    1Y
    856.5K

    ZYME most recently traded 718,051 shares against a 3-month average daily volume of 1.0M.

    More News

    Read More
    News headline image
    Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks (NASDAQ:ZYME) Misses Q1 Estimates But August PDUFA Date for Zanidatamab Offers Key Regulatory Catalyst ↗
    Via Chartmill
    News headline image
    Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook ↗
    Via MarketBeat
    News headline image
    Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks Completes Acquisition of Theravance Biopharma
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks Announces Participation in Upcoming Investor Conferences
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks to Acquire Theravance Biopharma, Inc.
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks Announces Participation in Upcoming Investor Conferences
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Zymeworks (ZYME) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Capricorn Fund Makes a Huge Bet on Nerve Repair With 687,000 Share Axogen (AXGN) Investment Worth $22.4 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks Appoints Kristin Stafford as Chief Financial Officer
    From Zymeworks Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Zymeworks Inc. - Common Stock publicly traded?
    Yes, Zymeworks Inc. - Common Stock is publicly traded.
    What exchange does Zymeworks Inc. - Common Stock trade on?
    Zymeworks Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Zymeworks Inc. - Common Stock?
    The ticker symbol for Zymeworks Inc. - Common Stock is ZYME on the Nasdaq Stock Market
    What is the current price of Zymeworks Inc. - Common Stock?
    The current price of Zymeworks Inc. - Common Stock is 29.26
    When was Zymeworks Inc. - Common Stock last traded?
    The last trade of Zymeworks Inc. - Common Stock was at 11/05/26 02:04 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.